Table 1.
Baseline characteristics of HCC patients
| Items | HCC patients (N = 278) |
|---|---|
| Demographic features | |
| Age (years), mean ± SD | 58.4 ± 9.3 |
| Gender, No. (%) | |
| Female | 55 (19.8) |
| Male | 223 (80.2) |
| History of HB, No. (%) | |
| No | 40 (14.4) |
| Yes | 238 (85.6) |
| History of liver cirrhosis, No. (%) | |
| No | 81 (29.1) |
| Yes | 197 (70.9) |
| Clinical features | |
| Child‐Pugh stage, No. (%) | |
| A | 231 (83.1) |
| B | 47 (16.9) |
| PS score, No. (%) | |
| 0 | 218 (78.4) |
| 1 | 60 (21.6) |
| Tumor nodule number, No. (%) | |
| Unifocal | 152 (54.7) |
| Multifocal | 126 (45.3) |
| Largest tumor size, No. (%) | |
| <5.0 cm | 154 (55.4) |
| ≥5.0 cm | 124 (44.6) |
| BCLC stage, No. (%) | |
| A | 128 (46.0) |
| B | 150 (54.0) |
| Liver function indexes | |
| ALT (U/L), median (IQR) | 27.1 (21.2‐39.4) |
| AST (U/L), median (IQR) | 36.2 (26.9‐48.5) |
| ALP (U/L), median (IQR) | 105.1 (81.3‐144.7) |
| TBIL (μmol/L), median (IQR) | 15.1 (10.8‐25.7) |
| Tumor markers | |
| AFP (ng/mL), median (IQR) | 32.7 (5.2‐1079.7) |
| CEA (ng/mL), median (IQR) | 2.7 (2.0‐4.4) |
| CA199 (U/mL), median (IQR) | 13.1 (5.3‐29.1) |
Abbreviations: AFP, alpha‐fetoprotein; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; BCLC, Barcelona clinic liver cancer; CA199, carbohydrate antigen 199; CEA, carcinoembryonic antigen; HB, hepatitis B; HCC, hepatocellular carcinoma; IQR, interquartile range; PS score, performance status score; SD, standard deviation; TBIL, total bilirubin.